Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Angela Ortega-Bermudez

Internal Medicine Henderson, NV Doctor of Osteopathy

NPI 1982873360 CMS profile 90459

2847 Saint Rose Pkwy Ste 150, Henderson, NV 89052

Open in the dashboard

General payments

$1,490

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Angela Ortega-Bermudez of Henderson, NV is reported in the CMS Open Payments database as having received $1,490 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $132 1
2024 General $125 1
2023 General $24 1
2022 General $18 1
2020 General $320 20
2019 General $871 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Angela Ortega-Bermudez
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Angela Ortega-Bermudez were reported at $132. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Angela Ortega-Bermudez Internal Medicine median Middle half National median
2019 $871 $159 $48–$570 $163
2020 $320 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $18 $141 $42–$496 $149
2023 $24 $149 $45–$519 $160
2024 $125 $154 $47–$537 $164
2025 $132 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $205 10 payments
  2. Abbott Laboratories $143 2 payments
  3. Pfizer Inc. $141 13 payments
  4. Actelion Pharmaceuticals US, Inc. $132 1 payment
  5. Novo Nordisk Inc $124 9 payments
  6. Amgen Inc. $120 6 payments
  7. Sanofi-Aventis U.S. LLC $106 6 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $105 5 payments
  9. Merck Sharp & Dohme Corporation $97 6 payments
  10. AbbVie, Inc. $94 5 payments
  11. Other $223 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,470 76 payments
  2. Education $20 2 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $205 10 payments
  2. OPSUMIT $132 1 payment
  3. UPTRAVI $132 1 payment
  4. CARDIOMEMS $125 1 payment
  5. Ozempic $112 8 payments
  6. STEGLATRO $97 6 payments
  7. JANUVIA $97 6 payments
  8. BYDUREON $96 1 payment
  9. CREON $94 5 payments
  10. EUCRISA $93 7 payments
  11. Other $1,116 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 146 drugs

Part D claims

10,231

Median for Internal Medicine: 777

Drug cost

$713,191

Median for Internal Medicine: $73,373

Branded share of claims

16.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 155 $221,636
Jardiance Empagliflozin Brand 108 $117,788
Eliquis Apixaban Brand 70 $83,356
Mounjaro Tirzepatide Brand 20 $35,157
Xarelto Rivaroxaban Brand 26 $28,714
Farxiga Dapagliflozin Propanediol Brand 24 $28,482
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 20 $26,237
Vascepa Icosapent Ethyl Brand 26 $22,587
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 21 $19,453
Tradjenta Linagliptin Brand 20 $19,038

The 10 drugs with the highest cost, of 146 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$17,979

Of which drugs: $2,393

Medicare patients

58

Average age 73

Services billed

230

44 women, 14 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 52%
Diabetes 31%
Ischemic heart disease 31%
Heart failure 26%
Chronic kidney disease 26%
Cancer 26%
Osteoporosis 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record